The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2024 | Safety & efficacy of T-DXd with chemotherapy & immunotherapy in gastric cancer
Filippo Pietrantonio, MD, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, explores the DESTINY-Gastric03 trial (NCT04379596), which evaluated the safety and efficacy of trastuzumab deruxtecan (T-DXd) with chemotherapy and immune checkpoint inhibitors in gastric cancer. Patient selection, particularly those with CPS ≥1, is crucial to maximizing the benefit of immunotherapy. The trial aimed to optimize the safety profile while preserving efficacy, offering insights into how future trials might refine patient selection to enhance therapeutic outcomes. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
